Recent Updates
Recently added Catalysts

cefdinir

Phase 2

Acute Otitis Media | Small molecule | ENT |Abbott Laboratories|Last Updated: Mar 27, 2008

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
UNCONTROLLED
Total Trials1
Total Enrollment447
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT00645203Safety and Efficacy Study of Cefdinir Oral Suspension, in Pediatric Subjects to Treat Acute Otitis MediaPHASE2 COMPLETED 447Jul 1, 2002 -Mar 27, 200822 United States, Chile +5
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Bacteriological Response
30 days
Clinical response
30 days
Change in the otoscopic findings
30 days
Secondary Endpoints
Physical exam; Vital signs; Use of concomitant medications
59 days
Adverse events assessment
45 days with follow-up to a satisfactory conclusion
Laboratory evaluations
30 days
Unlock Study Endpoints
Study Design & Arms
AllocationNON_RANDOMIZED
MaskingNONE
ModelSINGLE_GROUP
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
1OTHER -
Interventions
NameTypeDescription
cefdinirDRUGcefdinir oral suspension, 25 mg/kg once daily for 10 days
Unlock Study Design Details
Eligibility Criteria
Age Range6 Months — 4 Years
SexALL
Healthy VolunteersNo
Study Sites22

Inclusion Criteria: * Male and female children between 6 months and 4 years of age * Weight does not exceed 40 kg * Clinical diagnosis is acute otitis media * Have evidence of middle ear fluid * At risk for persistent or recurrent otitis media * Generally in good health Exclusion Criteria: * Sens...

Countries:United StatesChileCosta RicaDominican RepublicGuatemalaIsraelPanama
Unlock Eligibility Criteria